Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs
Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c
Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st
A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s
Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe
Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cer
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl